ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential ...

RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

CRISPR Therapeutics AG (NASDAQ ... with several companies making advancements in similar therapeutic areas. Beam Therapeutics' BEAM-101 and Tessera Therapeutics' in vivo editing programs, while not ...

CRISPR Therapeutics AG (NASDAQ ... Beam Therapeutics' BEAM-101 and Tessera Therapeutics' in vivo editing programs, while not immediate threats, represent potential future competition.

This, despite significant erosion in both metrics. For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company ...

CRISPR Therapeutics CRSP reported fourth-quarter 2024 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company recorded ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...